OBJECTIVE: We evaluated the long-term outcome of neonates receiving extracorporeal membrane oxygenation (ECMO) for congenital diaphragmatic hernia (CDH). Study design A retrospective review of all 73 neonates with CDH supported with ECMO in the United Kingdom between 1991 and 2000, with follow-up to January 2003. Information was from hospital charts and from communication with family doctors and pediatricians. Median follow-up period for survivors was 67 months. RESULTS: 46 infants (63%) were weaned from ECMO, 42 (58%) survived to hospital discharge, and 27 (37%) survived to age 1 year or more. A higher birth weight, higher 5-minute Apgar score, and postnatal diagnosis were "pre-ECMO" predictors of long-term survival. Comorbidity was common in long-term survivors: 13 (48%) had respiratory symptoms, 16(59%) had gastrointestinal problems, and 6 (19%) had severe neurodevelopmental problems. Only 7 children were free of significant neurodevelopmental deficit and required no further medical or surgical intervention. CONCLUSION: Using the current referral criteria, ECMO can be used to support the sickest neonates with CDH. However, there is significant mortality in the first year of life, and long-term physical and neurodevelopmental morbidity remains in the majority of survivors.
OBJECTIVE: We evaluated the long-term outcome of neonates receiving extracorporeal membrane oxygenation (ECMO) for congenital diaphragmatic hernia (CDH). Study design A retrospective review of all 73 neonates with CDH supported with ECMO in the United Kingdom between 1991 and 2000, with follow-up to January 2003. Information was from hospital charts and from communication with family doctors and pediatricians. Median follow-up period for survivors was 67 months. RESULTS: 46 infants (63%) were weaned from ECMO, 42 (58%) survived to hospital discharge, and 27 (37%) survived to age 1 year or more. A higher birth weight, higher 5-minute Apgar score, and postnatal diagnosis were "pre-ECMO" predictors of long-term survival. Comorbidity was common in long-term survivors: 13 (48%) had respiratory symptoms, 16(59%) had gastrointestinal problems, and 6 (19%) had severe neurodevelopmental problems. Only 7 children were free of significant neurodevelopmental deficit and required no further medical or surgical intervention. CONCLUSION: Using the current referral criteria, ECMO can be used to support the sickest neonates with CDH. However, there is significant mortality in the first year of life, and long-term physical and neurodevelopmental morbidity remains in the majority of survivors.
Authors: Kevin P Lally; Pamela A Lally; Krisa P Van Meurs; Desmond J Bohn; Carl F Davis; Bradley Rodgers; Jatinder Bhatia; Golde Dudell Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: Stanley J Crankson; Saud A Al Jadaan; Mohammed A Namshan; Abdullah A Al-Rabeeah; Omar Oda Journal: Pediatr Surg Int Date: 2006-02-03 Impact factor: 1.827
Authors: Jennifer R Benjamin; Kathryn E Gustafson; P Brian Smith; Kirsten M Ellingsen; K Brooke Tompkins; Ronald N Goldberg; C Michael Cotten; Ricki F Goldstein Journal: J Pediatr Surg Date: 2013-04 Impact factor: 2.545
Authors: L van den Hout; I Sluiter; S Gischler; A De Klein; R Rottier; H Ijsselstijn; I Reiss; D Tibboel Journal: Pediatr Surg Int Date: 2009-09 Impact factor: 1.827
Authors: David J Field; Richard Firmin; Denis V Azzopardi; Frances Cowan; Edmund Juszczak; Peter Brocklehurst Journal: BMC Pediatr Date: 2010-04-19 Impact factor: 2.125